PMID- 27649045
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180910
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 91
IP  - 12
DP  - 2016 Dec
TI  - A retrospective comparative outcome analysis following systemic therapy in 
      Mycosis fungoides and Sezary syndrome.
PG  - E491-E495
LID - 10.1002/ajh.24564 [doi]
AB  - Cutaneous T-cell lymphomas (CTCL), with few exceptions, remain incurable and 
      treatment is largely palliative. We performed a retrospective analysis of 
      systemic treatment outcomes of patients diagnosed with MF/SS. We identified 223 
      patients with MF/SS evaluated at a single institution from 1997 to 2013. Disease 
      stage at diagnosis, time of treatment, and treatments received were 
      retrospectively analyzed using our CTCL database. The primary endpoint was time 
      to next treatment (TTNT). Treatment outcomes were analyzed using Kaplan-Meier 
      method and comparisons among groups were made using log-rank analysis. A superior 
      TTNT was associated with retinoid or interferon therapies when compared with HDAC 
      inhibitors or systemic chemotherapy. Retinoids and interferon were associated 
      with superior TTNT in both limited-stage and advanced stage disease. 
      Extracorporeal photophoresis (ECP) had a superior TTNT in Sezary Syndrome. HDAC 
      inhibitors and chemotherapy were associated with inferior TTNT in both limited 
      stage disease and advanced stage disease. With the exception of interferon, 
      retinoids, or ECP, durable responses are rarely achieved with systemic therapies 
      in MF/SS patients, particularly those with advanced-stage disease. Therefore, 
      clinical trial participation with novel agents should be encouraged. Am. J. 
      Hematol. 91:E491-E495, 2016. (c) 2016 Wiley Periodicals, Inc.
CI  - (c) 2016 Wiley Periodicals, Inc.
FAU - Hanel, Walter
AU  - Hanel W
AD  - Department of Internal Medicine, University of Michigan Comprehensive Cancer 
      Center, Ann Arbor, Michigan.
FAU - Briski, Robert
AU  - Briski R
AD  - Department of Internal Medicine, Division of Hematology/Oncology, University of 
      Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
FAU - Ross, Charles W
AU  - Ross CW
AD  - Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann 
      Arbor, Michigan.
FAU - Anderson, Thomas F
AU  - Anderson TF
AD  - Department of Dermatology, University of Michigan Comprehensive Cancer Center, 
      Ann Arbor, Michigan.
FAU - Kaminski, Mark S
AU  - Kaminski MS
AD  - Department of Internal Medicine, Division of Hematology/Oncology, University of 
      Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
FAU - Hristov, Alexandra C
AU  - Hristov AC
AD  - Department of Dermatology and Pathology, University of Michigan Comprehensive 
      Cancer Center, Ann Arbor, Michigan.
FAU - Wilcox, Ryan A
AU  - Wilcox RA
AD  - Department of Internal Medicine, Division of Hematology/Oncology, University of 
      Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Retinoids)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Histone Deacetylase Inhibitors/*therapeutic use
MH  - Humans
MH  - Interferons/*therapeutic use
MH  - Middle Aged
MH  - Mycosis Fungoides/*drug therapy
MH  - Photopheresis/*methods
MH  - Retinoids/*therapeutic use
MH  - Retrospective Studies
MH  - Sezary Syndrome/*drug therapy
MH  - Treatment Outcome
EDAT- 2016/09/21 06:00
MHDA- 2017/06/22 06:00
CRDT- 2016/09/21 06:00
PHST- 2016/07/22 00:00 [received]
PHST- 2016/08/27 00:00 [revised]
PHST- 2016/09/17 00:00 [accepted]
PHST- 2016/09/21 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
PHST- 2016/09/21 06:00 [entrez]
AID - 10.1002/ajh.24564 [doi]
PST - ppublish
SO  - Am J Hematol. 2016 Dec;91(12):E491-E495. doi: 10.1002/ajh.24564.